# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...
Senti Biosciences, Inc. (NASDAQ:SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-ge...
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, a...